Today is Rare Disease Day. The NORD database lists over 1300 diseases and the global rare disease list (RARE List™) is comprised of about 7,000 different rare diseases affecting more than 300 million people worldwide. This is a day to build awareness, understanding and recognize the amazing patients and families that deal with these incredibly […]Read Full Article
Welcome to the Blue Fin Group Information Library. Our consultants regularly publish white papers, case studies and articles, lead workshops, deliver speaking engagements, and share opinions on topics of interest to decision makers in the healthcare industry.
You don’t become an industry leader without having alot to say—click on the video vignettes below to hear our expert’s perspectives on a range of topics.
Blue Fin Group is often sought out as an expert commentator by industry publications — featuring our latest thinking and timely insights on the issues that matter most to the healthcare industry.
Blue Fin Group keeps a lens trained on many facets of the healthcare industry, and our white papers focus on singular topics that are relevant and timely. Known for our out-of-the-box thinking, these insights provide a deeper dive or different viewpoint from what others in the industry provide.
Case studies that show the transformation from challenge to solution. Each one details the existing situation, Blue Fin Group’s unique approach, the solution deployed, and the results achieved on behalf of the client. At Blue Fin Group, we deliver Deep Knowledge. Powerful Results.
Deep knowledge, unique insights and powerful perspectives focused on the healthcare industry, provided by Blue Fin Group associates.
Addressing these questions can help you take your patient support services strategy from “good to great”: Do the unique characteristics of your product, its patients and their prescribers truly warrant the need for support services? If so, which services should you provide and for how long? Right-fit services need to be based on analysis of […]Read Full Article
It’s such an amazing time to be working in healthcare from a market access, and more broadly, a commercialization perspective. We are seeing more and more innovative and transformative medicines come to market in therapeutic areas where such treatment did not exist before. We are seeing diseases that were once death sentences become chronic diseases […]Read Full Article
A market-wide longitudinal patient database creates great potential for driving business value for a specialty drug manufacturer. It can support a deep understanding of patients, their holistic situations and their treatment histories. It can enable laser-focused strategy and program development. It can create the ability to predict who will be future patients of specific therapies, […]Read Full Article
A recent blog post described some of the business questions that can be answered by creating a market-wide longitudinal patient database. PHI de-identification is the key enabler for market-wide longitudinal patient integrity, and this blog post will expand on this theme. We’ll look at two scenarios that can enable a market-wide longitudinal patient database. The first […]Read Full Article
I took my son to Disneyland last year. I tell everyone now that visiting Disney is like the movie Groundhog Day – you have to go for at least 2 days as you’ll always mess up the first day and you need the second day to get it right. Day 1 we were a little […]Read Full Article
The coming year is full of uncertainty for pharmaceutical manufacturers and one critical proposed change may have been overlooked. While the fate of the Affordable Care Act, and the implications of any repeal or modification have dominated most discussions, relatively little focus has been placed on the potential impact of House Speaker Paul Ryan’s intentions […]Read Full Article
Who will be my future patients? What are the signals of a patient ready for my product? Who will likely be compliant and stay on therapy? Who will not? Why will Rxs not get converted to starts? Why will patients discontinue? These questions are all fair game but they require varying degrees of patient longitudinal […]Read Full Article